SynthesisAlimentary pharmacology & therapeutics2019
Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.
Synthesis in Alimentary pharmacology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07704255 (Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- To eradicate or not?Frontiers in medicine · 2026Pooled it
- Debate on the relationship betweenFrontiers in microbiology · 2024Pooled it
- Systematic review: gastrointestinal infection and incident inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2020Pooled it
- The exposome and inflammatory bowel disease: a framework for primary and primordial prevention.Nature reviews. Gastroenterology & hepatology · 2026Review
- Effect ofTherapeutic advances in gastroenterology · 2026Review
- Review
- Prevalence of gastric cancer and its associated mortality among patients undergoing upper gastrointestinal endoscopy at a tertiary level hospital in Tanzania.BMC gastroenterology · 2025Article
- The Controversies in the Relationship BetweenJournal of clinical medicine · 2025Review
- Eradication ofIranian journal of microbiology · 2025Article
- Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health.Journal of Crohn's & colitis · 2025Review
- Research advances in the pathogenesis and therapeutic interventions of Helicobacter pylori and atrial fibrillation.Frontiers in cardiovascular medicine · 2025Review
- Role of gut microbiota andWorld journal of gastroenterology · 2024Review
- Impact ofDiseases (Basel, Switzerland) · 2024Review
- Bibliometric analysis of the correlation between H. pylori and inflammatory bowel disease.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Review
- Roles of the components of theFuture microbiology · 2024Review
- Immunological relationship betweenCentral-European journal of immunology · 2024Review
- Detecting potential causal relationship between inflammatory bowel disease and rosacea using bi-directional Mendelian randomization.Scientific reports · 2023Article
- Immune response modulation in inflammatory bowel diseases byWorld journal of gastroenterology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundAccumulating data support a protective role of Helicobacter pylori against inflammatory bowel diseases (IBD), which might be mediated by strain-specific constituents, specifically cagA expression.
aimTo perform a systematic review and meta-analysis to more clearly define the association between CagA seropositivity and IBD.
methodsWe identified comparative studies that included sufficient detail to determine the odds or risk of IBD, Crohn's disease (CD) or ulcerative colitis (UC) amongst individuals with vs without evidence of cagA expression (eg CagA seropositivity). Estimates were pooled using a random effects model.
resultsThree clinical studies met inclusion criteria. cagA expression was represented by CagA seropositivity in all studies. Compared to CagA seronegativity overall, CagA seropositivity was associated with lower odds of IBD (OR 0.31, 95% CI 0.21-0.44) and CD (OR 0.25, 95% CI 0.17-0.38), and statistically nonsignificant lower odds for UC (OR 0.68, 95% CI 0.35-1.32). Similarly, compared to H pylori non-exposed individuals, H pylori exposed, CagA seropositive individuals had lower odds of IBD (OR 0.26, 95% CI 0.16-0.41) and CD (OR 0.23, 95% CI 0.15-0.35), but not UC (OR 0.66, 0.34-1.27). However, there was no significant difference in the odds of IBD, CD or UC between H pylori exposed, CagA seronegative and H pylori non-exposed individuals.
conclusionWe found evidence for a significant association between CagA seropositive H pylori exposure and reduced odds of IBD, particularly CD, but not for CagA seronegative H pylori exposure. Additional studies are needed to confirm these findings and define underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.